Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 184

1.

Extensive Emperipolesis of Neoplastic Lymphocytes by Mesothelial Cells in Pleural Effusion Cytology in a Case of a Mediastinal T-Cell Lymphoblastic Lymphoma: A Rare but Diagnostically Useful Phenomenon.

Haefliger S, Rebetez J, Buser PJ, Dirnhofer S, Bubendorf L.

Acta Cytol. 2019 Sep 17:1-5. doi: 10.1159/000502711. [Epub ahead of print]

PMID:
31527381
2.

Correlation of ROS1 Immunohistochemistry With ROS1 Fusion Status Determined by Fluorescence In Situ Hybridization.

Huang RSP, Smith D, Le CH, Liu WW, Ordinario E, Manohar C, Lee M, Rajamani J, Truong H, Li J, Choi C, Li J, Pati A, Bubendorf L, Buettner R, Kerr KM, Lopez-Rios F, Marchetti A, Marondel I, Nicholson AG, Öz AB, Pauwels P, Penault-Llorca F, Rossi G, Thunnissen E, Newell AH, Pate G, Menzl I.

Arch Pathol Lab Med. 2019 Sep 11. doi: 10.5858/arpa.2019-0085-OA. [Epub ahead of print]

PMID:
31509456
3.

Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.

Alborelli I, Leonards K, Rothschild SI, Leuenberger LP, Savic Prince S, Mertz KD, Poechtrager S, Buess M, Zippelius A, Läubli H, Haegele J, Tolnay M, Bubendorf L, Quagliata L, Jermann P.

J Pathol. 2019 Aug 30. doi: 10.1002/path.5344. [Epub ahead of print]

PMID:
31471895
4.

The Paris System for reporting urinary cytology in daily practice with emphasis on ancillary testing by multiprobe FISH.

Vlajnic T, Gut A, Savic S, Bubendorf L.

J Clin Pathol. 2019 Aug 29. pii: jclinpath-2019-206109. doi: 10.1136/jclinpath-2019-206109. [Epub ahead of print]

PMID:
31467041
5.

Immunocytochemistry for ARID1A as a potential biomarker in urine cytology of bladder cancer.

Dugas SG, Müller DC, Le Magnen C, Federer-Gsponer J, Seifert HH, Ruiz C, Savic Prince S, Vlajnic T, Zellweger T, Mertz KD, Bacon JVW, Wyatt AW, Rentsch CA, Bubendorf L.

Cancer Cytopathol. 2019 Sep;127(9):578-585. doi: 10.1002/cncy.22167. Epub 2019 Aug 6.

PMID:
31386310
6.

Analysis of AR/ARV7 Expression in Isolated Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer (SAKK 08/14 IMPROVE Trial).

Hench IB, Cathomas R, Costa L, Fischer N, Gillessen S, Hench J, Hermanns T, Kremer E, Mingrone W, Mestre RP, Püschel H, Rothermundt C, Ruiz C, Tolnay M, Burg PV, Bubendorf L, Vlajnic T, Sakk SGFCCR.

Cancers (Basel). 2019 Aug 1;11(8). pii: E1099. doi: 10.3390/cancers11081099.

7.

Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study.

Alborelli I, Generali D, Jermann P, Cappelletti MR, Ferrero G, Scaggiante B, Bortul M, Zanconati F, Nicolet S, Haegele J, Bubendorf L, Aceto N, Scaltriti M, Mucci G, Quagliata L, Novelli G.

Cell Death Dis. 2019 Jul 11;10(7):534. doi: 10.1038/s41419-019-1770-3.

8.

PD-L1 testing of non-small cell lung cancer using different antibodies and platforms: a Swiss cross-validation study.

Savic S, Berezowska S, Eppenberger-Castori S, Cathomas G, Diebold J, Fleischmann A, Jochum W, Komminoth P, McKee T, Letovanec I, Jasarevic Z, Rössle M, Singer G, von Gunten M, Zettl A, Zweifel R, Soltermann A, Bubendorf L.

Virchows Arch. 2019 Jul;475(1):67-76. doi: 10.1007/s00428-019-02582-0. Epub 2019 May 24.

PMID:
31127385
9.

Immunocytochemistry for predictive biomarker testing in lung cancer cytology.

Jain D, Nambirajan A, Borczuk A, Chen G, Minami Y, Moreira AL, Motoi N, Papotti M, Rekhtman N, Russell PA, Savic Prince S, Yatabe Y, Bubendorf L; IASLC Pathology Committee.

Cancer Cytopathol. 2019 May;127(5):325-339. doi: 10.1002/cncy.22137. Epub 2019 May 3. Review.

PMID:
31050216
10.

A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project.

Kerr KM, Thunnissen E, Dafni U, Finn SP, Bubendorf L, Soltermann A, Verbeken E, Biernat W, Warth A, Marchetti A, Speel EM, Pokharel S, Quinn AM, Monkhorst K, Navarro A, Madsen LB, Radonic T, Wilson J, De Luca G, Gray SG, Cheney R, Savic S, Martorell M, Muley T, Baas P, Meldgaard P, Blackhall F, Dingemans AM, Dziadziuszko R, Vansteenkiste J, Weder W, Polydoropoulou V, Geiger T, Kammler R, Peters S, Stahel R; Lungscape Consortium.

Lung Cancer. 2019 May;131:95-103. doi: 10.1016/j.lungcan.2019.03.012. Epub 2019 Mar 15.

PMID:
31027705
11.

Consistency and reproducibility of next-generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens.

Pisapia P, Malapelle U, Roma G, Saddar S, Zheng Q, Pepe F, Bruzzese D, Vigliar E, Bellevicine C, Luthra R, Nikiforov YE, Mayo-de-Las-Casas C, Molina-Vila MA, Rosell R, Bihl M, Savic S, Bubendorf L, de Biase D, Tallini G, Hwang DH, Sholl LM, Vander Borght S, Weynand B, Stieber D, Vielh P, Rappa A, Barberis M, Fassan M, Rugge M, De Andrea CE, Lozano MD, Lupi C, Fontanini G, Schmitt F, Dumur CI, Bisig B, Bongiovanni M, Merkelbach-Bruse S, Büttner R, Nikiforova MN, Roy-Chowdhuri S, Troncone G; Molecular Cytopathology Meeting Group.

Cancer Cytopathol. 2019 May;127(5):285-296. doi: 10.1002/cncy.22134. Epub 2019 Apr 25.

PMID:
31021538
12.

Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08).

Curioni-Fontecedro A, Perentes JY, Gelpke H, Xyrafas A, Bouchaab H, Mach N, Matzinger O, Stojcheva N, Frueh M, Weder W, Cathomas R, Gargiulo P, Bubendorf L, Pless M, Betticher D, Peters S; Swiss Group of Clinical Cancer Research (SAKK).

Br J Cancer. 2019 May;120(10):968-974. doi: 10.1038/s41416-019-0447-0. Epub 2019 Apr 16.

13.

Urinary Calprotectin loses specificity as tumour marker due to sterile leukocyturia associated with bladder cancer.

Bausch K, Roth E, Heinz S, Horst D, Mathia S, Vlajnic T, Bubendorf L, Westhoff T, Wetterauer C, Seifert HH, Ebbing J.

PLoS One. 2019 Mar 14;14(3):e0213549. doi: 10.1371/journal.pone.0213549. eCollection 2019.

14.

Handling and reporting of pelvic lymphadenectomy specimens in prostate and bladder cancer: a web-based survey by the European Network of Uropathology.

Prendeville S, Berney DM, Bubendorf L, Compérat E, Egevad L, Hes O, Kristiansen G, Oxley J, van Leenders GJLH, Varma M, van der Kwast T.

Histopathology. 2019 May;74(6):844-852. doi: 10.1111/his.13818. Epub 2019 Apr 1.

PMID:
30604878
15.

Compressed Sensing Radial Sampling MRI of Prostate Perfusion: Utility for Detection of Prostate Cancer.

Winkel DJ, Heye TJ, Benz MR, Glessgen CG, Wetterauer C, Bubendorf L, Block TK, Boll DT.

Radiology. 2019 Mar;290(3):702-708. doi: 10.1148/radiol.2018180556. Epub 2019 Jan 1.

PMID:
30599102
16.

Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer.

Yatabe Y, Dacic S, Borczuk AC, Warth A, Russell PA, Lantuejoul S, Beasley MB, Thunnissen E, Pelosi G, Rekhtman N, Bubendorf L, Mino-Kenudson M, Yoshida A, Geisinger KR, Noguchi M, Chirieac LR, Bolting J, Chung JH, Chou TY, Chen G, Poleri C, Lopez-Rios F, Papotti M, Sholl LM, Roden AC, Travis WD, Hirsch FR, Kerr KM, Tsao MS, Nicholson AG, Wistuba I, Moreira AL.

J Thorac Oncol. 2019 Mar;14(3):377-407. doi: 10.1016/j.jtho.2018.12.005. Epub 2018 Dec 18.

PMID:
30572031
17.

Exploring the spatiotemporal genetic heterogeneity in metastatic lung adenocarcinoma using a nuclei flow-sorting approach.

Lorber T, Andor N, Dietsche T, Perrina V, Juskevicius D, Pereira K, Greer SU, Krause A, Müller DC, Savic Prince S, Lardinois D, Barrett MT, Ruiz C, Bubendorf L.

J Pathol. 2019 Feb;247(2):199-213. doi: 10.1002/path.5183. Epub 2018 Dec 28.

PMID:
30350422
18.

Tissue microarray analysis delineate potential prognostic role of Annexin A7 in prostate cancer progression.

Leighton X, Bera A, Eidelman O, Bubendorf L, Zellweger T, Banerjee J, Gelmann EP, Pollard HB, Srivastava M.

PLoS One. 2018 Oct 15;13(10):e0205837. doi: 10.1371/journal.pone.0205837. eCollection 2018.

19.

Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry - Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort.

Rulle U, Tsourti Z, Casanova R, Deml KF, Verbeken E, Thunnissen E, Warth A, Cheney R, Sejda A, Speel EJ, Madsen LB, Nonaka D, Navarro A, Sansano I, Marchetti A, Finn SP, Monkhorst K, Kerr KM, Haberecker M, Wu C, Zygoura P, Kammler R, Geiger T, Gendreau S, Schulze K, Vrugt B, Wild P, Moch H, Weder W, Ciftlik AT, Dafni U, Peters S, Bubendorf L, Stahel RA, Soltermann A.

J Thorac Oncol. 2018 Dec;13(12):1851-1863. doi: 10.1016/j.jtho.2018.08.2034. Epub 2018 Sep 18.

20.

Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers.

Peters S, Stahel R, Bubendorf L, Bonomi P, Villegas A, Kowalski DM, Baik CS, Isla D, Carpeno JC, Garrido P, Rittmeyer A, Tiseo M, Meyenberg C, de Haas S, Lam LH, Lu MW, Stinchcombe TE.

Clin Cancer Res. 2019 Jan 1;25(1):64-72. doi: 10.1158/1078-0432.CCR-18-1590. Epub 2018 Sep 11.

PMID:
30206164

Supplemental Content

Loading ...
Support Center